<DOC>
	<DOCNO>NCT02600819</DOCNO>
	<brief_summary>This study evaluate safety tolerability elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) fixed-dose combination ( FDC ) HIV-1 infect adult end stage renal disease ( ESRD ) chronic hemodialysis ( HD ) Week 48 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Efficacy E/C/F/TAF Fixed Dose Combination ( FDC ) HIV-1 Infected Adults Chronic Hemodialysis</brief_title>
	<detailed_description />
	<criteria>Key Currently stable antiretroviral regimen ≥ 6 consecutive month Plasma HIV1 RNA concentration &lt; 50 copies/mL ≥ 6 month precede screen visit HIV1 RNA &lt; 50 copies/mL screen No documented history HIV1 resistance EVG , FTC , lamivudine ( 3TC ) TFV history switch EVG , FTC , 3TC TFV due concern resistance CD4+ T cell count ≥ 200 cells/μL ESRD estimate glomerular filtration rate ( eGFR ) &lt; 15 mL/min CockcroftGault formula creatinine clearance On chronic HD ≥ 6 month prior screen Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm^3 ; platelet ≥ 50,000/mm^3 ; hemoglobin ≥ 8.5 g/dL ) Key Hepatitis B coinfection Any clinical history , condition , test result , opinion Investigator , would make individual unsuitable study unable comply dose requirement Administration investigational agent ( unless approve Gilead Sciences ) . Participation clinical trial , include observational trial , without prior approval sponsor prohibit participate trial . History presence allergy intolerance study drug components A new AIDSdefining condition ( exclude CD4+ T cell count percentage criterion ) diagnose within 30 day prior screen , exception oropharyngeal candidiasis Received solid organ bone marrow transplant Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>end stage renal disease ( ESRD )</keyword>
	<keyword>hemodialysis ( HD )</keyword>
	<keyword>open-label</keyword>
	<keyword>HIV-1 Infection</keyword>
</DOC>